Rare HIV-positive individuals shed light on how body could effectively handle infection

Feb 24, 2011

Although untreated HIV infection eventually results in immunodeficiency (AIDS), a small group of people infected with the virus, called elite suppressors (0.5 percent of all HIV-infected individuals), are naturally able to control infection in the absence of antiretroviral therapy, or HAART. Elite suppressors and HIV- infected individuals treated with HAART have similar levels of virus in the blood stream.

However, levels of HIV integrated into are much lower in elite suppressors compared to levels in cells from HIV-infected individuals on HAART, according to a study by University of Pennsylvania School of Medicine researchers published in PLoS Pathogens.

Elite suppressors are thought to have a more effective to HIV; specifically, more effective killer T cells, the subgroup of that kill cells infected with viruses. HIV is an RNA virus that converts its RNA genome into DNA intermediates in order to replicate. One important step in the HIV life cycle is integration - where HIV DNA inserts into the chromosomes of human helper T cells.

Cells that contain the integrated form of HIV DNA and are metabolically less active appear to be resistant to antiretroviral therapy and persist in the host, forming a latent reservoir. It will be important to understand why the HIV reservoir is lower in elite suppressors than in HIV infected individuals on HAART. To begin to address this question, it would be interesting to see if the level of integration would be lower still after placing elite suppressors on HAART.

The investigators speculate that therapeutic vaccinations aimed at generating killer similar to those in elite suppressors may be effective against the treatment resistant latent reservoir.

The cohort of elite suppressors was characterized by NIH researchers who also contributed to the study.

Explore further: Bacterial communities of female genital tract have impact on inflammation, HIV risk

More information: F Nawaz et al. The genotype of early-transmitting HIV gp120s promotes α4β7 reactivity, revealing α4β7+/CD4+ T cells as key targets in mucosal transmission. PloS Pathogens. DOI: ppat1001301 (2011).

Related Stories

A cure for HIV could be all in the 'mix'

Aug 18, 2010

Current HIV treatments do not eradicate HIV from host cells but rather inhibit virus replication and delay the onset of AIDS. However, a new research published in BioMed Central's open access journal, AIDS Research & Therapy descri ...

Exhausted B cells fail to fight HIV

Jul 14, 2008

HIV tires out the cells that produce virus-fighting proteins known as antibodies, according to a human study that will be published online July 14 in the Journal of Experimental Medicine.

Waking up dormant HIV

Mar 16, 2009

HAART (highly active anti-retroviral therapy) has emerged as an extremely effective HIV treatment that keeps virus levels almost undetectable; however, HAART can never truly eradicate the virus as some HIV always remains ...

Human testis harbors HIV-1 in resident immune cells

Nov 27, 2006

Researchers have demonstrated HIV replication within resident immune cells of the testis, providing an explanation for the persistence of virus in semen even after effective highly active antiretroviral therapy. The related ...

HIV measurement is questioned

Sep 27, 2006

Preliminary U.S. research indicates the HIV RNA level in untreated HIV-infected patients has little value in predicting the rate of CD4 cell count decrease.

Recommended for you

HIV reservoirs remain obstacles to cure

May 19, 2015

Antiretroviral therapy (ART) has proven lifesaving for people infected with HIV; however, the medications are a lifelong necessity for most HIV-infected individuals and present practical, logistical, economic ...

Microclinics help keep Kenyan HIV patients in care

May 18, 2015

A team led by researchers from UC San Francisco, Organic Health Response, and Microclinic International is reporting results of a study that showed significant benefits of microclinics—an innovative intervention ...

'Redesigned' antibodies may control HIV

May 18, 2015

With the help of a computer program called "Rosetta," researchers at Vanderbilt University have "redesigned" an antibody that has increased potency and can neutralize more strains of the AIDS-causing human ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.